CYP2D6 is primarily responsible for the metabolism of clomiphene

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 2008, Pages 101-105

  Ghobadi, Cyrus ^a   Gregory, Anne ^a   Crewe, H Kim ^a,b   Rostami Hodjegan, Amin ^a,b   Lennard, Martin S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Clomiphene; CYP2D6, Metabolism; Enclomiphene; Zuclomiphene

Indexed keywords

CLOMIFENE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENCLOMIFENE; KETOCONAZOLE; QUINIDINE; RECOMBINANT ENZYME; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; LIVER PARENCHYMA; LYMPHOBLASTOID CELL; PROTEIN CONTENT; PROTEIN EXPRESSION; METABOLISM; PHYSIOLOGY;

CLOMIPHENE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; QUINIDINE;

EID: 43749083482     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.101     Document Type: Article

References (24)

1. Hughes, E., Collins, J. and Vandekerckhove, P.: Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. Cochrane Database Syst Rev. CD000056 (2000).
2. Rostami-Hodjegan, A., Lennard, M. S., Tucker, G. T. and Ledger, W. L.: Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril. 81: 1187-1193 (2004).
3. Goetz, M. P., Knox, S. K., Suman, V. J., et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 101: 113-121 (2007).
4. Ruenitz, P. C.: Rabbit liver microsomal metabolism of enclomiphene. Drug Metab Dispos. 9: 456-460 (1981).
5. Ruenitz, P. C., Bagley, J. R. and Mokler, C. M.: Metabolism of clomiphene in the rat. Estrogen receptor affinity and antiestrogenic activity of clomiphene metabolites. Biochem Pharmacol. 32: 2941-2947 (1983).
6. Ernst, S., Hite, G., Cantrell, J. S., Richardson, A., Jr. and Benson, H. D.: Stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure-activity relationships. J Pharm Sci. 65: 148-150 (1976).
7. Van Campenhout, J., Borreman, E., Wyman, H. and Antaki, A.: Induction of ovulation with cisclomiphene. Am J Obstet Gynecol. 115: 321-327 (1973).
8. Clark, J. H. and Guthrie, S. C.: Agonistic and antagonistic effects of clomiphene citrate and its isomers. Biol Reprod. 25: 667-672 (1981).
9. Glasier, A. F., Irvine, D. S., Wickings, E. J., Hillier, S. G. and Baird, D. T.: A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles. Hum Reprod. 4: 252-256 (1989).
10. Schmidt, G. E., Kim, M. H., Mansour, R., Torello, L. and Friedman, C. I.: The effects of enclomiphene and zuclomiphene citrates on mouse embryos fertilized in vitro and in vivo. Am J Obstet Gynecol. 154: 727-736 (1986).
11. Young, S. L., Opsahl, M. S. and Fritz, M. A.: Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Fertil Steril. 71: 639-644 (1999).
12. Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S. and Gillam, E. M.: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 30: 869-874 (2002).
13. Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E. and Chenery, R. J.: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica. 25: 261-270 (1995).
14. Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T. and Woods, H. F.: Use of quinidine inhibition to define the role of the sparteine/ debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 247: 242-247 (1988).
15. Baranczewski, P., Stanczak, A., Sundberg, K., et al.: Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep. 58: 453-472 (2006).
16. Barter, Z. E., Bayliss, M. K., Beaune, P. H., et al.: Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 8: 33-45 (2007).
17. Johnson, T. N., Tucker, G. T., Tanner, M. S. and Rostami-Hodjegan, A.: Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 11: 1481-1493 (2005).
18. Price, P. S., Conolly, R. B., Chaisson, C. F., et al.: Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol. 33: 469-503 (2003).
19. Du Bois, D. and Du Bois, E. F.: A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 5: 303-311; discussion 312-303 (1989).
20. Mikkelson, T. J., Kroboth, P. D., Cameron, W. J., Dittert, L. W., Chungi, V. and Manberg, P. J.: Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 46: 392-396 (1986).
21. Wilkinson, G. R. and Shand, D. G.: Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 18: 377-390 (1975).
22. Lobell, M. and Sivarajah, V.: In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers. 7: 69-87 (2003).
23. Szutu, M., Morgan, D. J., McLeish, M., et al.: Pharmacokinetics of intravenous clomiphene isomers. Br J Clin Pharmacol. 27: 639-640 (1989).
24. Beverage, J. N., Sissung, T.M., Sion, A. M., Danesi, R. and Figg, W. D.: CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 96: 2224-2231 (2007).